A venture company specializing in new drug development
Biotech venture companies are actively engaged in the field of life science, which encompasses the development of drugs and medical devices as well as regenerative medicine. DWTI is a venture company that specializes in the discovery and development of new drugs by drawing on our experience and prowess in biotechnology.
Why is there a need for biotech venture companies?
1 Unmet medical needs, diseases for which no cure has been found, are expanding
2 Our mission in society is to take on high-risk, high-return challenges
3 The mainstream of drug discovery in the U.S.
For many years, development moved forward for drugs which targeted large patient populations. For this reason, the scale of R&D investment was an important factor. Advances in technology, however, have now made it possible to develop and deliver more effective drugs to smaller, more specific patient groups. Consequently, the emphasis now is on the efficiency of R&D investment. In this context, because biotech venture companies are able to move forward with development by zooming in on specific target diseases and patient populations, they are said to have high development efficiency. In the U.S., depending on the year, about 60% to 80% of new drugs are developed by biotech ventures.
(Source: Ministry of Economy, Trade and Industry, Current Status and Issues of Biotech Venture Companies [November 15, 2017])